Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07348354

Standardization and Application of Pure Platelet-Rich Plasma in Improving Sperm Function

Phase 1: Standardize and validate pure platelet-rich plasma (P-PRP) protocol

Aims:

To validate a standardized double-spin protocol for preparing pure platelet-rich plasma (P-PRP) in an IVF laboratory setting by assessing its platelet yield, purity, and reproducibility.

Outcomes

Primary outcome Platelet concentration in PRP Absolute platelet count in P-PRP and fold-increase compared to whole blood Secondary outcome Platelet recovery (%): (Platelet count in P-PRP × P-PRP volume) / (Whole blood platelet count × blood volume) × 100 Purity: White blood cell (WBC) concentration in P-PRP Growth factors :e.g.. VEGF, PDGF-AB, TGF-β, IGF-1… concentrations in plasma of PPP and P-PRP preparation Reproducibility Metrics: Coefficient of variation (CV%), intraclass correlation coefficient (ICC), and Bland-Altman limits of agreement for technical and biological duplicates.

Phase 2: Examine the effect of pure platelet-rich plasma (P-PRP) on sperm parameters Hypotheses and objectives Hypotheses The investigator hypothesizes that co-culture of semen with pure platelet-rich plasma (P-PRP) enhances sperm quality by increasing motility compared to standard culture medium without P-PRP (control group).

Primary outcome

- To compare total sperm motility after 24 hours of co-culture between semen samples co-cultured with P-PRP versus a control group (without P-PRP).

Secondary outcome

* To compare sperm parameters after other timepoints of co-culture between semen samples co-cultured with P-PRP versus a control group (without P-PRP). * To compare the morphology and DNA Fragmentation Index (DFI) in semen samples after 24-hour co-culture with P-PRP versus control.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female volunteer aged 18-45 years, willing to donate their blood
  • Adequate sperm samples (raw sample TMS > 5 x 106)
  • BMI <30 kg/m2

Exclusion criteria

  • Concurrent administration of other agents such as prednisolone, intravenous immunoglobulin, or G-CSF
  • Drug addiction
  • Underlying uncontrolled genital infections, diabetes or hypertension, chromosomal or uterine abnormalities, genetic, hematologic, immunological, or endocrine disorders
  • Chronic disease, systemic disease, or cancers
  • Blood diseases (sepsis, thrombocytopenia)
  • Do not agree to donate blood
  • Use of supplements containing antioxidants within the past 3 months
  • Administration of anticoagulants or NSAIDs at least 7 days before P-PRP infuse
  • Haemoglobin < 11g/dL, platelet count < 150000 mm3

Treatment and study plan

Standard culture

Other

Only sperm culture

PRP culture

Other

PRP 2-5% will be co-culture with sperm

Primary outcomes

  1. Phase I: Platelet concentration in PRP

    Time frame: Baseline

    Absolute platelet count in P-PRP

  2. Phase II: total sperm motility

    Time frame: Up to 24 hours

    total sperm motility after 24 hours of co-culture between semen samples co-cultured with P-PRP versus a control group (without P-PRP).

Secondary outcomes

  1. Phase I: Platelet recovery (%)

    Time frame: Baseline

    Platelet recovery (%)=(Platelet count in P-PRP × P-PRP volume) / (Whole blood platelet count × blood volume) × 100 in PRP

  2. VEGF

    Time frame: Up to 8 weeks

    Growth factors VEGF concentration

  3. TGF-β

    Time frame: Up to 8 weeks

    Growth factors PDGF-A concentration

  4. IGF-1

    Time frame: Up to 8 weeks

    Growth factors IGF-1concentration

  5. Sperm progressive motility

    Time frame: Up to 24 hours

    Sperm progressive motility

  6. Sperm non-progressive motility

    Time frame: Up to 24 hours

    Sperm non-progressive motility

  7. Sperm immotility

    Time frame: Up to 24 hours

    Sperm immotility

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 16, 2026
Registry last updated
Jan 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.